BIOCRATES Life Sciences AG and Selexis SA join forces to further optimize high-yield mammalian cell cultures
Biocrates Life Sciences AG and Selexis SA have entered into a co-development agreement to further increase drug substance yields from mammalian cell cultures. Because most protein therapeutics require specific post-translational modifications (e.g., glycosylation) to exert their full therapeutic efficacy, mammalian cell systems have become the standard for the manufacture of most pharmaceutical recombinant proteins. The comparatively high costs of mammalian cell culture processes, coupled with their low yields, have spurred interest in the development of novel methods to optimize and boost specific productivity and titers of recombinant proteins. Wombat Capital Ltd. provided expert advisory services to BIOCRATES for this collaboration.
“Our partnership with Selexis provides us with a unique opportunity to cooperate with an industry expert in cell culture development and optimization—a highly promising application of metabolomics,” said Elgar Schnegg, Chief Executive Officer of BIOCRATES. “We are confident that metabolomics will help to further fine-tune the characteristics of the high-performance cell culture systems developed by Selexis.” An opinion shared by Dr Igor Fisch, Chief Executive Officer and co-founder of Selexis, who said: “In BIOCRATES, we have found an ideal partner to further advance our cell culture development and eventually deliver to our clients optimized solutions to bring their cell culture processes from lab bench to cGMP manufacturing in record time.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
